Lynn Seely, MD, is the Chief Executive Officer of Myovant Sciences, a healthcare company focused on developing innovative treatments for women’s health and prostate cancer. Dr. Seely is an endocrinologist with over 20 years of drug development and executive leadership experience. Prior to Myovant, she served as Chief Medical Officer at Medivation from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies.

Dr. Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.